Adaptive Biotechnologies, an immune profiling company based in Seattle, has been working through partnerships with research groups worldwide to better understand T cell responses to Lyme and other Tick-Borne illnesses and how these immune signatures might inform the development of a T cell-based diagnostic. As an example of how we have done this in other diseases please see our recent work in COVID-19 published by Snyder et al 2020. Our focus right now is identifying investigators who have banked patient samples or the ability to collect samples during the coming season. Since our assay studies the cellular response in diseases like Lyme we would run T-cell Receptor (TCR) sequencing on whole blood (2 mLs), buffy coat (~3 million cells), or DNA (18 ug) from either. 

Heidi Chapman, PhD
Partnership Management Specialist
603-630-5502 - Seattle, WA
hchapman@adaptivebiotech.com